The mechanism of action of the anti-oestrogen tamoxifen (TAM) is unclear, but it is apparent that TAM has both oestrogen receptor (ER) and non-ER mediated cytostatic activity. Previous observations by our group (Kang and Perry, 1993) and others (Reddel et al., 1984; Dickson et al., 1990) have shown that the time-and dose-dependent growth inhibitory effects of TAM have a biphasic character. TAM may have important biological effects via novel pathways, such as through modulation of transforming growth factor P (TGF-P1) activity (Butta et al., 1992) . TGF-P1 has either growth inhibitory or growth stimulatory properties, depending on the concentration and cell type (Roberts et al., 1985) .
TGF-PI appears to be an important negative regulator of breast cancer cell growth. ER( + ) MCF-7 breast cancer cells (Roberts et al., 1985; Knabbe et al., 1987) , and four ER( -) breast cancer cell lines including MDA-231 (Arteaga et al., 1988) secrete and are inhibited by TGF-pl. It also appears that TGF-P, may be a mediator of TAMinduced cytostasis (Manni et al., 1991) . Anti-oestrogens induce TGF-P3 activity in ER( +) MCF-7 cells in vitro (Knabbe et al., 1987) , in ER( -) human fetal fibroblast in vitro (Colletta et al., 1990) , and in both ER( + ) and ER( -) human breast cancer in vivo (Butta et al., 1992) . However, the induction of TGF-PI is not an absolute requirement for TAM-induced cytostasis, as demonstrated by other models including long-term passage MCF-7 cells (Zugmaier and Lippman, 1990 ) and the ER( +) T47-D breast cancer cell line (Murphy and Dotzlaw, 1989) . Since TGF-PI is rapidly degraded, with the preform having a half-life of 2 h and the active form only 2 min, active synthesis is required for this protein to be expressed (Wakefield et al., 1987) . Recent work in our laboratory has shown that TAM can induce growth stimulation at low dose or growth inhibition and apoptosis at higher doses in either ER( + ) MCF-7 or ER( -) MDA-231 human breast cancer cells (Table I; Perry et al., 1995) . TAM for 6 h resulted in a slight but non-significant decrease of TGF-13I protein, accompanied by a slight increase in cell growth (Table I) and an increase in the number of cells entering S-phase (Table II) certain models can increase death-associated mRNAs (Owens et al., 1991) . Cycloheximide alone had no effect on TGF-P3 expression (data not shown).
Effects of TAM on TGF-f3, gene copy number Because the TAM-induced increase in TGF-P3 expression occurred over a relatively short time scale, it seemed unlikely that this increase was due to gene amplification. Nonetheless, TAM can rapidly effect cellular genes (Lau et al., 1991) . We therefore determined if the effects of TAM on TGF-1B, expression were due to amplification of the TGF-P1 gene.
Genomic DNA was isolated from breast cancer cells treated with 10 JIM TAM for up to 48 h, and subjected to Southern blotting. There was no significant difference in TGF-PI gene copy number in MCF-7 and MDA-231 cells under control conditions, and TAM had no significant effect on TGF-,1 DNA gene copy number (data not shown). Thus, the TAMinduced increase in TGF-P1 expression was not due to gene amplification. TAM treatment for up to 120 h also did not increase TGF-P1 gene copy number (data not shown).
Effects of Anti-TGF-P, antibody on TAM-induced DNA cleavage TAM induction of TGF-P3 highly correlated with internucleosomal DNA cleavage (Figure 3) . Therefore, the ability of TAM to induce internucleosomal DNA cleavage was determined in the presence or absence of anti-TGF-P1
antibody. TAM alone induced DNA cleavage typical of apoptosis in MCF-7 and MDA-231 cells (Figure 6 ). The addition of an irrelevant isotype control antibody failed to inhibit TAM-induced DNA cleavage. However, the addition of anti-TGF-Pf antibody inhibited TAM-induced DNA cleavage in both cell lines.
Discussion
TAM has time-and dose-dependent effects on TGF-,13 expression and cell cycle kinetics in MCF-7 and MDA-231 cells. The effects of TAM on cell cycle kinetics have been well described by our laboratory (Kang and Perry, 1993) and others (Osborne et al., 1983) . TAM blocks both MCF-7 and MDA-231 cells in GI/Go, indicating that the effect of TAM on cell cycle kinetics is independent of ER. The results of this study show a good correlation between TAM induction of TGF-P1 and cell cycle blockade in GI/Go, which may at least partially explain the cytostatic effects of TAM. The time course of TAM-induced alterations in TGF-P3 expression and cell cycle kinetics was similar to the time course of TAMinduced apoptosis seen in our previous study (Perry et al., 1995) . TAM induction of TGF-P1 correlated strongly with internucleosomal DNA cleavage. Also, addition of anti-TGF-PI antibody completely inhibited TAM-induced DNA cleavage. These data suggest that TGF-P1 is an important mediator of TAM-induced apoptosis.
The effects of TAM on TGF-P1 expression are complex and independent of ER status. TAM treatment for 6 h caused a slight decrease in TGF-P1 expression which was accompanied by an increase in cell growth and the percentage of cells in S-phase. This decrease in TGF-P1 expression was probably caused at the translational level since TGF-13I mRNA levels were increased during this time interval. TAM treatment of > 12 h caused an increase in TGF-13I expression which correlated highly with and preceded the observed G1/ Go arrest. This induction of TGF-P, was accompanied by a parallel increase in TGF-P, mRNA and occurred in the absence of TGF-P, gene amplification, suggesting TAM has regulatory effects at the transcriptional or post-transcriptional levels.
TAM induction of TGF-1,B precedes apoptosis, since TGF-P, mRNA was induced by 6-12 h and DNA cleavage and apoptosis in our previous study was not observed until 12-24h (Table I ) (Perry et al., 1995) . In the present study addition of anti-TGF-P1 antibody inhibited TAM-induced internucleosomal DNA cleavage (Figure 6 ), a strong indication that induction of TGF-PJ by TAM triggers apoptosis.
Cycloheximide treatment significantly increased accumulation of TAM-induced TGF-P1 mRNA, an increase typically seen with death-associated mRNAs (Owens et al., 1991) . TGF-P3 may trigger apoptosis by activation of signal transduction pathways (Rotello et al., 1991) , by effects on c-myc expression (Moses et al., 1990; Taetle et al., 1993) , or by effects of GI phase cyclins (Mercer, 1993) .
Although MCF-7 cells are slightly more sensitive to TAMinduced apoptosis (Perry et al., 1995) , in this study we found no significant difference between the two cells lines in the degree or time course of TAM induction of TGF-pf. Oestrogen inhibits TAM-induced cytostasis and apoptosis in MCF-7 cells but not in MDA-231 cells, suggesting that TAM induces apoptosis via both ER-dependent and ER-independent pathways (Perry et al., 1995) . However, oestrogen did not inhibit TAM-induced TGF-PI expression in the present study, indicating that TAM may induce TGF-,B through an ER-independent mechanism. TAM has previously been shown to elicit TGF-13I production in MCF-7 cells (Knabbe et al., 1987) , as well as from fibroblasts lacking ER (Colletta et al., 1990 been shown to have effects on several immediate early response genes such as fos and jun (Lau et al., 1991; Nephew et al., 1993) , whose products bind to the control regions of genes containing activator protein 1 (AP-1) specific sequences. TAM has also been shown to inhibit growth factor induced AP-l-dependent transcriptional activity (Phillips et al., 1993) . AP-1 binds to phorbol ester-responsive elements which have been identified in the potential TGF-P1 regulatory domain (Scotto et al., 1990; Nutt et al., 1991) . In the present study TAM induction of TGF-P1 mRNA was not inhibited by cycloheximide, suggesting that at least some of the effects of TAM on TGF-P1 may be direct, rather than indirectly mediated through effects on other genes.
The results of this study along with our previous work suggest that TGF-P, may be an important mediator of TAMinduced cell cycle kinetic changes, cytostasis and apoptosis.
The effects of TAM on TGF-1,3 expression appear to be independent of ER status and may be due to a direct regulatory effect on TGF-,B transcription. Whether these results will hold true in other models in vitro or in vivo remains to be determined. Understanding the mechanisms whereby TAM exerts anti-tumour activity may lead to the development of novel and potentially useful approaches for treating cancer.
